期刊： CARDIO-ONCOLOGY, 2022; 8 (1)
Background Programmed death-1 (PD-1) and programmed death- ligand 1 (PD-L1) inhibitors, such as pembrolizumab, nivolumab and atezolizumab, are major c......
期刊： CARDIO-ONCOLOGY, 2022; 8 (1)
Background During cancer treatment, patients have a significantly higher risk of developing cardiovascular complications such as hypertension. In this......
